About

Join STAT’s biotech team in San Francisco as they take the stage to help you digest all the biggest stories from the year’s biggest investor conference. Expect several surprise guests to stop by as well, to react to the latest happenings in nearby Union Square at the J.P. Morgan Healthcare Conference. Drinks and light bites will be served.

STAT is also hosting a free JPM Co-Working Space January 8th-10th, exclusive to STAT+ Subscribers. All rooms are first come first serve, learn more here.

Register now

Please note – Space is limited, and this event has been known to draw quite a crowd. All attendees must register, but attendance priority will be given on a first come, first serve basis on the day of the event.

Agenda & Session Details

6:00-6:45 p.m. PT – Arrival + Registration

Drinks and light bites will be served.

6:45-6:50 p.m. PT – Welcome Remarks  Sponsor Session

Jacob Aptekar, M.D., Ph.D., vice president, trial design solutions lead, Medidata AI, Dassault Systèmes (sponsor speaker)

6:50-6:55 p.m. PT – Opening From STAT

Matthew Herper, senior writer, medicine; editorial director of events, STAT

6:55 – 7:00 p.m. PT – NYC’s Leadership in Life Sciences and Tech  Sponsor Session

NYC is emerging as a leader where tech intersects with life sciences. Leading NY scientific institutions are investing in data science, AI/machine learning, computational biology, and health tech, creating new commercial opportunities for startups, and generating interest from investors like Deerfield, Two Bear, Polaris, and Versant. Hear more about how you can be a part of this transformation.

Susan Rosenthal, SVP, Life Sciences & Healthcare, New York City Economic Development Corporation (sponsor speaker)

7:00-7:25 p.m. PT – The FDA’s Gene Therapy Boss on the Potential for a Revolution

Peter Marks is perhaps the most important – and controversial – drug regulator in the world. He was key to the development of Covid vaccines. In gene therapy, he has taken an aggressive position on the FDA’s role in catalyzing innovation. He’ll join STAT’s award-winning biotech columnist for a lively conversation.

Peter Marks, M.D., Ph.D., director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Adam Feuerstein, senior writer, biotech, STAT (moderator)

7:25-7:35 p.m. PT – The Future of Clinical Development: AI Everywhere  Sponsor Session

We are at an inflection point where AI shifts from being a supportive tool to seamlessly embedded into daily work to impact decision making, risk reduction and sustainability. In this session: explore how the next wave of GenAI will accelerate the development of safer, more effective therapies while ensuring data privacy, regulatory compliance, and the reliability, and interpretability.

Jacob Aptekar, M.D., Ph.D., vice president, trial design solutions lead, Medidata AI, Dassault Systèmes (sponsor speaker)

Afrah Shafquat, Ph.D., senior data scientist II, Medidata AI, Dassault Systèmes (sponsor speaker)

Matthew Herper, senior writer, medicine; editorial director of events, STAT (moderator)

7:35-8:05 p.m. PT – Biotech in 2024: The Year Ahead

Join a STAT-curated panel of some of the top names in biotech and pharma to look ahead at the year to come. Will the upturn in the M&A market continue? Will new medicines deliver on investors’ hopes? What can we learn from the past 12 months – or the first day of J.P. Morgan?

Kristina Burow, managing director, ARCH Venture Partners

Matt Gline, CEO, Roivant

Ted Love, M.D., chair of the board of directors, Biotechnology Innovation Organization (BIO)

Myrtle Potter, president & chief executive officer, Sumitomo Pharma America

Damian Garde, national biotech reporter, STAT (moderator)

8:05 – 8:10 p.m. PT – Closing from STAT

Matthew Herper, senior writer, medicine; editorial director of events, STAT

8:10-9:00 p.m. PT – Networking Reception